Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Liposome-encapsulated Daunorubicin-Cytarabine

Review the clinical trials studying liposome-encapsulated daunorubicin-cytarabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients with High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Status: Active
Location: 186 locations
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 179 locations
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger than 60 Years Old
Status: Active
Location: 4 locations
CPX-351 for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: 3 locations
Vyxeos in Treating Patients with Intermediate and High-Risk Acute Myeloid Leukemia Who Have Failed an Initial Cycle of Standard Induction Chemotherapy
Status: Active
Location: 2 locations
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants with Relapsed, Refractory or Untreated Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CPX-351 (VYXEOS) for the Treatment of Secondary Myeloid Neoplasms in Patients Under 22 Years Old
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Vyxeos and Gilteritinib for the Treatment of Relapsed or Refractory FLT-3 Mutated Acute Myeloid Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
CPX-351 with Gemtuzumab Ozogamicin for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
CPX-351 With or Without Venetoclax in Treating Patients with Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Palbociclib or Tazemetostat in Combination with CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Temporarily Closed to Accrual
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
Status: Active
Location: 299 locations